Quest Diagnostics Common Stock Net 2010-2025 | DGX

Quest Diagnostics common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
  • Quest Diagnostics common stock net for the quarter ending March 31, 2025 was $2M, a 0% increase year-over-year.
  • Quest Diagnostics common stock net for 2024 was $0.002B, a 0% decline from 2023.
  • Quest Diagnostics common stock net for 2023 was $0.002B, a 0% decline from 2022.
  • Quest Diagnostics common stock net for 2022 was $0.002B, a 0% decline from 2021.
Quest Diagnostics Annual Common Stock Net
(Millions of US $)
2024 $2
2023 $2
2022 $2
2021 $2
2020 $2
2019 $2
2018 $2
2017 $2
2016 $2
2015 $2
2014 $2
2013 $2
2012 $2
2011 $2
2010 $2
2009 $2
Quest Diagnostics Quarterly Common Stock Net
(Millions of US $)
2024-12-31 $2
2024-09-30 $2
2024-06-30 $2
2024-03-31 $2
2023-12-31 $2
2023-09-30 $2
2023-06-30 $2
2023-03-31 $2
2022-12-31 $2
2022-09-30 $2
2022-06-30 $2
2022-03-31 $2
2021-12-31 $2
2021-09-30 $2
2021-06-30 $2
2021-03-31 $2
2020-12-31 $2
2020-09-30 $2
2020-06-30 $2
2020-03-31 $2
2019-12-31 $2
2019-09-30 $2
2019-06-30 $2
2019-03-31 $2
2018-12-31 $2
2018-09-30 $2
2018-06-30 $2
2018-03-31 $2
2017-12-31 $2
2017-09-30 $2
2017-06-30 $2
2017-03-31 $2
2016-12-31 $2
2016-09-30 $2
2016-06-30 $2
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31 $2
2014-09-30 $2
2014-06-30 $2
2014-03-31 $2
2013-12-31 $2
2013-09-30 $2
2013-06-30 $2
2013-03-31 $2
2012-12-31 $2
2012-09-30 $2
2012-06-30 $2
2012-03-31 $2
2011-12-31 $2
2011-09-30 $2
2011-06-30 $2
2011-03-31 $2
2010-12-31 $2
2010-09-30 $2
2010-06-30 $2
2010-03-31 $2
2009-12-31 $2
2009-09-30 $2
2009-06-30 $2
2009-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $18.282B $9.872B
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
Stock Name Country Market Cap PE Ratio
DaVita (DVA) United States $11.202B 14.29
Encompass Health (EHC) United States $10.408B 23.33
Chemed (CHE) United States $8.501B 27.28
Option Care Health (OPCH) United States $5.259B 25.21
Elanco Animal Health (ELAN) United States $4.190B 9.27
RadNet (RDNT) United States $3.686B 79.02
Amedisys (AMED) United States $3.011B 21.29
LifeStance Health (LFST) United States $2.576B 0.00
Addus HomeCare (ADUS) United States $1.840B 21.32
Astrana Health (ASTH) United States $1.573B 35.26
U.S Physical Therapy (USPH) United States $1.025B 26.14
Pennant (PNTG) United States $0.907B 36.29
Aveanna Healthcare Holdings (AVAH) United States $0.886B 0.00
Atai Life Sciences (ATAI) Germany $0.294B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.006B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
Psychemedics (PMD) United States $0.000B 0.00